Hengrui Pharma 恒瑞医药
15 significant filings since 30 May 2026: 10 on buyback and 5 on equity incentive. The latest, on 18 Sep 2026: 恒瑞医药关于首次回购公司A股股份的公告.
自 30 May 2026 起有 15 份重大公告：buyback 10 份、equity incentive 5 份。最新一份（18 Sep 2026）：恒瑞医药关于首次回购公司A股股份的公告。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 For this company, 1 of 17 rated reports was Neutral or lower. 本公司 17 份评级研报中 1 份为中性或以下。
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 24 Aug 2026 | 浦银国际证券 | 季昶阳 | Buy 买入 | ▼ | Neutral 中性 |
| 29 Oct 2024 | 交银国际证券 | 丁政宁,诸葛乐懿 | Buy 买入 | ▼ | Neutral 中性 |
| 4 Jul 2023 | 民生证券 | 王班,王维肖 | Outperform 增持 | ▲ | Buy 买入 |
| 16 Jan 2023 | 群益证券 | 王睿哲 | Buy 买入 | ▼ | Outperform 增持 |
| 18 Apr 2018 | 高华证券 | 陈子易 | Neutral 中性 | ▲ | Buy 买入 |
| 23 Jun 2017 | 高华证券 | 陈子易 | Buy 买入 | ▼ | Neutral 中性 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 中邮证券 | 盛丽华,陈灿 | Buy 买入 | 25 Aug 2026 | 3 | — |
| 浦银国际证券 | 季昶阳 | Neutral 中性 | 24 Aug 2026 | 2 | 50.00 |
| 国金证券 | 甘坛焕,姜铸轩 | Buy 买入 | 19 Jul 2026 | 4 | — |
| 西南证券 | 杜向阳 | Buy 买入 | 1 Jul 2026 | 3 | — |
| 东吴证券 | 朱国广 | Buy 买入 | 6 May 2026 | 1 | — |
| 中航证券 | 李蔚 | Buy 买入 | 22 Apr 2026 | 1 | — |
| 中银证券 | 刘恩阳 | Buy 买入 | 1 Apr 2026 | 1 | — |
| 群益证券 | 王睿哲 | Outperform 增持 | 28 Nov 2025 | 1 | 83.00 |
| 民生证券 | 王维肖 | Buy 买入 | 28 Oct 2025 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 3 of 17 reports. 每行为该券商近十二个月的最新研报；17 份中 3 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。